AMGN Jul 2023 265.000 call

OPR - OPR Prezzo differito. Valuta in USD.
0,0500
-0,1000 (-66,67%)
Al 11:20AM EDT. Mercato aperto.
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente0,1500
Aperto0,1500
Denaro0,0400
Lettera0,1200
Prezzo d'esercizio265,00
Scadenza2023-07-21
Min-Max giorno0,0500 - 0,1500
Contratto - Min-MaxN/D
Volume48
Open Interest2,41k
  • GlobeNewswire

    Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

    Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery